Mepsevii market report forecasts growth through 2035

The Business Research Company says the global Mepsevii market is expanding as rare disease therapies, genetic testing and orphan drug investment increase. The report points to North America’s lead in 2025 and faster growth ahead in Asia-Pacific.

Why it matters: - The Mepsevii market is tied to treatment access for Mucopolysaccharidosis VII, a rare inherited disorder with limited therapeutic options. - Growth in genetic testing and newborn screening is expanding the diagnosed patient pool, which can widen demand for enzyme replacement therapy. - The report’s forecast through 2035 signals continued commercial interest in ultra-rare disease treatment.

What happened: - The Business Research Company released its Mepsevii Market Report 2026, covering market size, trends and global forecasts for 2026-2035. - The report says Mepsevii market growth is being driven by advances in rare disease therapies and improved awareness of genetic disorders. - The company also made a free sample available in a sample request.

The details: - Mepsevii, or vestronidase alfa, is an enzyme replacement therapy approved for Mucopolysaccharidosis VII. - The treatment replaces beta-glucuronidase, the missing enzyme in MPS VII, to help break down harmful substances that build up in the body. - The report says historical market growth came from limited treatment options, recombinant enzyme production progress, orphan drug designations, better diagnostics and greater recognition of rare genetic diseases. - Future growth is expected from a broader rare disease pipeline, higher orphan drug investment, expanded genetic testing, more home-based infusion services and a stronger focus on patient quality of life. - Key trends include wider use of enzyme replacement therapies, greater attention to ultra-rare genetic disorders, demand for long-term disease management, personalized treatment approaches and earlier diagnosis. - The report says rising mucopolysaccharidosis diagnoses are helping drive the market, supported by improved diagnostic technology, better clinician awareness and broader genetic testing. - In March 2024, the Oregon Health Authority reported Illinois had a birth prevalence of 1 in 73,290 for MPS II in 2022, while Missouri had 1 in 96,297 in 2023. - The company also published a full market report.

Between the lines: - The report frames Mepsevii as part of a broader shift toward treating ultra-rare diseases with targeted biologics. - Home infusion services and personalized treatment point to a market that is moving beyond drug sales toward care delivery models. - The emphasis on early diagnosis suggests market growth depends as much on detection as on therapy availability.

What's next: - The report expects North America to remain the largest regional market in 2025 because of advanced healthcare infrastructure and broad access to genetic testing. - Asia-Pacific is projected to grow fastest during the forecast period as awareness, diagnostics and healthcare investment improve. - The report also includes coverage of Western Europe, Eastern Europe, South America, the Middle East and Africa.